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Abstract
Background: Enhanced recovery after surgery (ERAS) programmes aim to improve postoperative out-
comes. They are being utilized increasingly in hepatic surgery. This review aims to evaluate the impact of
ERAS programmes on outcomes following liver surgery.
Methods: EMBASE, MEDLINE, PubMed and the Cochrane Database were searched for trials comparing
outcomes in patients undergoing liver surgery utilizing ERAS principles with those in patients receiving
conventional care. The primary outcome was occurrence of postoperative complications within 30 days.
Secondary outcomes included length of stay (LoS), functional recovery and adherence to ERAS
protocols.
Results: Nine articles were included in the review, of which two were randomized controlled trials
(RCTs). Overall complication rates were 25.0% (range: 11.5–46.4%) in ERAS patients, and 31.0% (range:
11.8–46.2%) in conventional care patients. Significantly reduced overall complication rates following
ERAS care were demonstrated by a meta-analysis of the data reported in the two RCTs (odds ratio: 0.49,
95% confidence interval 0.28–0.84; P = 0.01) The median LoS reported by the studies was 5.0 days
(range: 2.5–7.0 days) in ERAS patients, and 7.5 days (range: 3.0–11.0 days) in non-ERAS patients.
Recovery milestones, when reported, were improved following ERAS care.
Conclusions: The adoption of ERAS protocols improves morbidity and LoS following liver surgery.
Future ERAS programmes should accommodate the unique requirements of liver surgery in order to
optimize postoperative outcomes.
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Introduction
Enhanced recovery after surgery (ERAS) programmes were intro-
duced initially in colorectal surgery, in which they have been asso-
ciated with improvements in postoperative length of stay (LoS)
and morbidity.1 They have since been adopted by multiple spe-
cialties, including orthopaedic surgery,2 gynaecology3 and breast
surgery.4
The underlying principle of ERAS is amultimodal perioperative
protocol to attenuate the inflammatory response and potentiate
patient rehabilitation following major surgery.5 The intention is to
prevent the problems associatedwith an exaggerated inflammatory
reaction to surgery, such as poor healing, infective complications
and organ dysfunction.6 This approach, incorporating intensive
optimization of mobility, gut function and analgesia,7 contributes
to expediting recovery and minimizing morbidity.
Enhanced recovery after surgery programmes reduce postop-
erative morbidity rates following a variety of surgical procedures.1
Liver resections have traditionally been associated with high mor-
tality andmorbidity rates.With current surgical and perioperative
management, mortality rates of <5% can be achieved.8 However,
morbidity rates remain high at 15–50%.9 Adopting ERAS proto-
cols may facilitate further improvement in surgical outcomes in
hepatic resection.
Recently, a number of publications have examined the applica-
tion of ERAS programmes to hepatic surgery. This review evalu-
ates the impacts of these programmes on morbidity and recovery
rates following liver surgery.
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Materials and methods
This study was conducted according to the PRISMA (preferred
reporting items for systematic reviews and meta-analyses) guide-
lines for meta-analysis.10 A literature search of EMBASE,
MEDLINE, PubMed and the Cochrane Database was performed
independently by two researchers in May 2013.
The databases were searched for the period 1966–2013
using the key terms ‘enhanced recovery’, ‘fast track’, ‘ERAS’ and
‘liver’, ‘hepatobiliary’, ‘hpb’. All abstracts were reviewed for rel-
evance. The full texts of relevant articles were subsequently
reviewed.
All trials assessing enhanced recovery following liver surgery
were included. Inclusion criteria required that the study should
clearly state the ERAS protocol, which should contain at least four
items of care considered to be contributory to an enhanced recov-
ery programme.11 Exclusion criteria discounted any studies
involving children aged 16 years and younger, and any studies that
reported the use of a non-standard care pathway or compared
ERAS protocols in both arms of the study.
All studies included in the final analysis were assessed by two
independent reviewers. Study quality and bias were assessed inde-
pendently using the Downs and Black score.12 Data were extracted
directly from the papers according to data extraction forms.
The primary outcome was the occurrence of any compli-
cation within 30 days postoperatively. The following markers
were assessed as secondary outcomes: LoS; time to the achieve-
ment of functional recovery; time to independent mobility;
time to resumption of diet, and time until first bowel motion/
flatus.
The meta-analysis was performed using RevMan Version 5.2
(Nordic Cochrane Centre, Copenhagen, Denmark). Dichotomous
data were analysed using the fixed-effects odds ratio. Heterogene-
ity was assessed using I2 and chi-squared tests and judged to be
significant if the I2-value was >50% and according to a P-value of
<0.05. The cut-off for statistical significance was set at P < 0.05.
When continuous quantitative data were not distributed nor-
mally, meta-analysis was not performed and a qualitative assess-
ment was utilized.
Results
Study characteristics
A total of 257 papers were identified. The PRISMA diagram is
shown in Fig. 1. Nine studies were included for review.13–21
Studies investigating outcomes in open hepatic surgery
included two randomized controlled trials (RCTs),16,17 two pro-
spective cohort studies 18,19 and one retrospective cohort study21
and two case–control studies.13,20 Two case–control trials com-
pared outcomes of ERAS protocols with those of conventional
care after laparoscopic surgery.14,15
The trials included spanned the period from 2008 to 2013. A
total of 522 patients underwent liver resection according to an
ERAS protocol and 316 were managed on a conventional care
pathway following liver resection. The median patient age was
60.0 years (range: 48.4–64.0 years) in the ERAS group and 52.5
years (range: 45.0–67.0 years) in the conventional care group. The
majority of the operations were for colorectal liver metastases or
hepatocellular carcinoma.Details of participant characteristics are
shown in Table 1. All studies explicitly described an ERAS proto-
col. A median of 11 (range: 8–19) ERAS items were utilized. The
257 records
identified through
database
searching
257 records after duplicates
removed
257 records
screened
19 full-text articles
assessed for
eligibility
9 studies included
in qualitative
synthesis
2 studies included
in qualitative
synthesis
(meta-analysis)
238 records
excluded
10 articles
excluded
Review articles
(n = 3)
ERAS in both
arms of study
(n = 3)
Not hepatic
resectional
surgery only (n = 4)
0 additional
records identified
through other
sources
Figure 1 PRISMA diagram illustrating the identification and selection
of studies for review
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individual components utilized and rates of adherence to the
protocol are displayed in Table 2.
Complications
All nine studies assessed complication rates.13–21 Median overall
complication rates were 25.0% (range: 11.5–46.4%) in ERAS
patients, and 31.0% (range: 11.8–46.2%) in conventional care
patients. However, Ni et al.17 observed a significantly reduced
overall complication rate in the ERAS group (Table 3), and a
meta-analysis of overall complication rates in the two RCTs16,17
shows that significantly fewer complications occurred after ERAS
surgery [I2 = 0%; odds ratio (OR): 0.49, 95% confidence interval
(CI) 0.28–0.84; P = 0.01]. Both Jones et al.16 and Ni et al.17
reported significantly fewer non-surgical complications in the
ERAS arms of their studies [7.0% versus 27.0% (P = 0.02) in Jones
et al.16; 12.5% versus 25.0% (P = 0.04) in Ni et al.17], but showed
no statistically significant difference in the occurrence of liver-
specific complications [15.0% in ERAS patients and 11.0% in
conventional care patients (P = 0.612) in Jones et al.16; 17.5% in
ERAS patients and 21.0% in conventional care patients (P = 0.55)
in Ni et al.17)] (Tables S1 and S2, online). Mortality rates were low
and were similar in both groups (Table 3).
Length of stay
The median LoS reported by the studies was 5.0 days (range:
2.5–7.0 days) in ERAS patients and 7.5 days (range: 3.0–11.0 days)
in non-ERAS patients. The three cohort studies reported amedian
LoS of 4.0 days18,21 and 5.0 days.19 All four studies that compared
ERASwith conventionalmanagement inopen liver surgery showed
a significantly reduced LoS in the ERAS groups.13,16,17,19 Neither of
the two laparoscopic studies14,15 identified a reduced LoS.However,
Stoot et al.15 reported reduced time to achieve functional recovery.
Functional recovery was reported by only three studies,15–17 all of
which showed a reduced time to recovery following ERAS care.
Five13,14,16,19,20 of the nine trials reported on readmission rates, but
observed no significant differences (Table 3).
Adherence
Three of the studies reported rates of adherence to the proto-
col.13,16,18 Jones et al.16 reported 100% adherence in all 19 ERAS
categories except the early removal of the indwelling urinary cath-
eter (IDC). Mackay and O’Dwyer18 reported prolonged use of i.v.
fluid administration beyond the first postoperative day. Rates of
intra-abdominal drain insertion and reduced feeding were also
reported (Table 2).
Parameters of recovery
Only three14,16,17 of the trials reported on the achievement of
individual recovery milestones. Time to flatus was signifi-
cantly reduced in the ERAS groups. Time to establishment
of oral diet and time to independent mobilization were either
comparable or improved in the ERAS groups when reported
(Table S3, online).
Discussion
This review investigated the effects of ERAS protocols on recovery
following liver resection. Three previous reviews11,22,23 have been
performed in this area, and have concluded that safety and fea-
sibility were satisfactory and that a reduced LoS does not result in
increased morbidity or mortality. However, these reviews11,22,23
included studies other than those concerned purely with ERAS
versus conventional care, did not report any RCTs and reviewed
only two studies comparing ERAS with conventional care after
open surgery. Since these reviews11,22,23 were released, five studies
have been published, including two RCTs. Therefore, in light
of this new evidence, it is important to review the current
recommendations.
The present review was limited because the small number of
RCTs prevents any meaningful meta-analysis. The majority of
studies were observational, which reduces the power of the review
and prevents optimal quantitative comparison. However, all trials
were procedure-specific and compared ERAS with conventional
recovery protocols and thus this review represents the current best
available evidence.
In concordance with the previous reviews on this subject,11,22,23
the current review observed that LoS is reduced by ERAS pro-
grammes, a result seen in all of the individual studies in open liver
resection. However, by contrast with the previous reviews, and in
line with the colorectal literature,1 complication rates in hepatic
surgery can also be reduced by ERAS protocols: a meta-analysis of
both published RCTs16,17 shows a significant reduction in overall
complication rates.
This reduction was not repeated in the non-RCT studies. This
may be related to study design and power. However, it is note-
worthy that the study conducted by Ni et al.17 featured the young-
est population of all the studies and both RCTs16,17 included
relatively fitter populations. Advanced age and American Society
of Anesthesiologists (ASA) class are both independent predictors
of morbidity following abdominal surgery24 and it is possible that
the younger and fitter populations of these studies16,17 progressed
better in an enhanced recovery protocol. Furthermore, Jones
et al.16 employed an ERAS programme incorporating 19 compo-
nents – more than in any other trial – and compliance with the
protocol was exceptionally high, a key consideration in the
conduct of ERAS programmes.25
Adherence was poorly reported: only three trials commented
on this aspect. The main areas of reported poor compliance were
i.v. fluid restriction, IDC removal and early mobility. Within the
literature on ERAS programmes in the context of colorectal
surgery, compliance is often not recorded or may be as low as
5%.25 Higher rates of compliance are associated with reduced LoS
and reduced compliance is associated with high readmission
rates.25 Hence adherence is clearly an area which has potential for
improvement in ERAS protocols following liver surgery.
Although the rates of general complications were observed to
have been reduced in the two RCTs, no difference in liver-specific
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surgical complications was observed. Liver resection offers a
unique set of postoperative circumstances as a result of the
process of liver regeneration, the anatomical complexity of biliary
drainage and intraoperative vascular inflow control, and the tran-
sient impairment of liver function following resection. It is there-
fore not surprising that an ERAS approach does not reduce
surgical complications in such patients.
Whereas ERAS protocols focus on pre- and postoperative con-
siderations, liver surgery provides an opportunity to optimize
intraoperative care. The minimizing of blood loss should reduce
liver-specific surgical complications.26–28 Raised central venous
pressure (CVP) has been shown to be associated with intra-
operative blood loss during liver resection.29 Six of the nine trials
covered in this review included a care component based on the
reduction of intraoperative fluid, but only two13,21 commented on
titration of i.v. fluid according to CVP. Jones et al.16 used goal-
directed fluid therapy guided by LiDCO cardiac output monitor
to prevent fluid overload, although they did this in the early
Table 1 Demographic and operative details reported in the studies of outcomes of enhanced recovery after surgery (ERAS) programmes
covered in this review
van Dam et al13 Sànchez-Pérez et al14 Stoot et al15 Jones et al16
ERAS/C ERAS/C ERAS/C ERAS/C
Patients, n 61/100 26/17 13/13 46/45
Age, years, median
(range)
62 (24–82)/60 (20–81) ns 58.3 (29–77)/52.5
(29–84) ns
55 (34–82)/45 (26–70) ns 64 (IQR 27–83)/67 (IQR
27–84) ns
ASA class, n (%)
I 11 (18)/14 (14) 0/0 3 (23)/6 (46) 0/2 (4.5)
II 42 (69)/64 (64) 13 (50)/8 (47) 9 (69)/6 (46) 43 (93)/38 (84.5)
III 8 (13)/22 (22) 13 (50)/9 (53) 1 (8)/1 (8) 3 (7)/5 (11)
IV –/– –/– –/– –/–
ns ns ns ns
Resections, n (%)
≥3 segments 51 (84)/79 (79) (≥2
segments)
0/0 0/0 21 (46)/12 (27)
<3 segments 10 (16)/21 (21) (<2
segments)
ns
26 (100)/17 (100)
ns
12 (92)/12 (92)
Segmentectomy (≥2)
1 (8)/1 (8)
Ns
25 (54)/33 (73)
POSSUM score higher in
ERAS group (P = 0.012)
Pathology, n (%)
CLM 51 (84)/72 (72) – Malignant 35 (76)/26 (58)
HCC 4 (7)/9 (9) 3 (12)/3 (18) 8 (62)/3 (23) –
Cholangio – 1 (4)/0 Benign –
Benign 4 (7)/14 (14) 14 (54)/14 (82) 5 (38)/10 (77) 1 (2)/9 (20)
Other metastases 2 (3)/4 (4)
ns
8 (31)/0
(P < 0.05)
ns 10 (22)/10 (22)
(P = 0.021)
Neoadjuvent therapy,
n (%)
38 (62)/33 (33) (P ≤ 0.001) NA NA 36 (78)/25 (56) (P = 0.021)
Cirrhosis NA NA NA NA
Sex, n (%)
Male 35 (57)/51 (51)
ns
15 (58)/10 (59)
ns
3 (23)/2 (15) ns 31 (67)/23 (51) ns
EBL, ml, median (range) 750 (0–5000)/800 (0–6000)
ns
Transfusion required
ERAS 19.2%; C 5.8%
(P < 0.05)
50 (50–200)/250 (50–800)
(P = 0.002)
350 (IQR 174–900)/340
(IQR 150–645) ns
Operating time, mins,
median (range)
220 (60–420)/270 (106–510)
(P < 0.001)
180 (60–345)/177 (80–300)
ns
118 (85–192)/180 (51–340)
ns
NA
Pringle time, mins,
mean (SD)
NA 7 (26.9)/5 (29.4) ns NA NA
Quality (Downs and
Black)
20/32 18/32 19/32 31/32
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postoperative period. It would appear that ERAS protocols in liver
surgery should incorporate both intraoperative and postoperative
components to maximize their gains.
Areas that were not explored by the studies covered in this
review included the use of a thoracic epidural.Although a thoracic
epidural is recommended in ERAS in the context of colorectal
surgery,30 its use has been questioned in liver surgery.31 There is
evidence suggesting that epidurals may impair recovery in liver
surgery, and that alternative methods of analgesia should be
considered.32,33
Furthermore, a small liver remnant may be a contraindication
to the administration of paracetamol.34 Paracetamol is routinely
utilized as the backbone of analgesic regimens,35 but in major
hepatic resections it is often withheld for fear of inducing liver
Ni et al17 Mackay & O’Dwyer18 Schultz et al19 Lin et al20 Connor et al21
ERAS/C ERAS/C ERAS/C ERAS/C ERAS/C
80/80 12/– 100/– 56/61 128/–
Mean 48.4 (±15.6)/mean
50.1 (±21.8) (P = 0.57)
60 (43–74)/– 64 (16–91)/– 57 (23–73)/55 (22–81) ns 63 (35–82)/–
7 (95)/78 (98) 4 (33.3)/– 29 (29)/– (I + II) 43 (76.5)/50 (82) (I + II) 104 (81)/–
4 (5)/2 (2) 7 (58.3)/– 46 (46)/– 11 (19.5)/10 (16) –/–
–/– 1 (8.3)/– 25 (25)/– 2 (4)/1 (2) 24 (19)/–
–/– –/– –/– –/– –/–
ns ns
73 (91)/69 (86) 3 (25)/– 32 (32)/– 19 (34)/21 (34) 64 (50)/–
7 (9)/11 (14)
ns
9 (75)/– 68 (68)/– 37 (66)/40 (66)
ns
64 (50)/–
– 12 (100) 77 (77) NA 84 (66)/–
71 (89)/76 (95) – 12 (12) 9 (7)/–
9 (11)/4 (5) – – 11 (9)/–
– – – 10 (8)/–
– ns – Other 11 (11) 14 (11)/–
NA NA NA NA NA
62 (78)/58 (73) ns NA NA NA NA
66 (83)/59 (74) ns 8 (66.7)/– 63 (63)/– 31 (58)/34 (56) NA
Mean 313 (±223.9)/mean
358.2 (±311.7) ns
NA NA 760 (IQR 0–2100)/850 (IQR
0–2300) ns
>0.5 l 67%, 0.5–1.0 l 26%,
>1 l 7%
Mean 141.2 (±57.4)/mean
132.1 (±36.9) ns
130 IQR (110–160) NA 110 (IQR 60–160)/125 (IQR
81–187) ns
NA
NA NA NA NA NA
27/32 18/32 22/32 21/32 21/32
ASA, American Society of Anesthesiologists, C, conventional care; CLM, colorectal liver metastases; EBL, estimated blood loss; IQR, interquartile
range; HCC, hepatocellular carcinoma; NA, not assessed; ns, no statistically significant difference; SD, standard deviation. Statistically significant
results are highlighted in bold.
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damage, which increases opiate requirements. At present,
further evaluation of analgesia in liver surgery within the con-
text of an ERAS programme is required to establish optimal
practice.
This review has highlighted the benefits of the application of
enhanced recovery principles following liver surgery.However, the
evidence supporting these principles stems from the literature on
colorectal surgery. Resectional liver surgery comes with its own set
of unique conditions whichmust be acknowledged when attempt-
ing to optimize the outcomes of patients following liver surgery. In
order to maximize the potential benefit of such programmes,
future research should aim to establish perioperative care plans
specific to liver surgery and should accommodate the unique
requirements of this operation.
Length of stay is not an ideal outcome by which to judge
the success of an ERAS programme because the factors that
make patients able to or keen to leave hospital are many.36 Func-
tional recovery was infrequently assessed in the present studies,
which offered only modest reporting of recovery milestones.
When recovery milestones were reported, ERAS protocols
resulted in either parity or some improvement in these out-
comes. Both recovery milestones and functional recovery have
been suggested as more meaningful than simple LoS in the
assessment of the success of an enhanced recovery protocol11
and should represent the measurement of success in future
programmes.
In summary, the evidence investigating ERAS following liver
surgery is limited and only two RCTS have been conducted.
However, postoperative LoS is reduced in the context of ERAS in
comparison with that in conventional care. Medical complication
rates seem to be reduced, although surgical morbidity remains
high and is as yet unaffected by ERAS protocols following liver
surgery. Future research should concentrate on perioperative care
components specific to liver surgery, such as optimal analgesic
regimens and intraoperative manipulations to reduce blood loss,
rather than simply transferring components from the literature on
colorectal surgery.
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Table 2 Care components of enhanced recovery after surgery (ERAS) programmes and adherence data (adherence rates are shown in
parentheses)
van Dam
et al13
Sànchez-Pérez
et al14
Stoot
et al15
Jones
et al16
Ni
et al17
Mackay &
O'Dwyer18
Schultz et al19 Lin et al20 Connor
et al21
Preoperative counselling X X (100%) X X (100%) X X X
Avoid bowel prep X (100%) X X X
Carb drinks up to 2 h
preoperatively
X X X (100%) X X (100%) Clear
fluids
X X
Avoid anaesthetic
pre-med
X X X (100%) X X X
VTE prophylaxis X (100%) X
Antibiotic prophylaxis X (100%) X (100%) X
Standard anaesthetic
protocol
X (95%) X X (100%) X
Ileus avoidance X X X (100%) X X Laxatives and
chewing gum
NGT avoidance X (3/61 had NGT) Removal at end of
surgery
X X (100%) X X Removed
immediately
postoperatively
X
Intraoperative warming X X (100%) X
Minimization of
preoperative fluids
X X X X (100%) X X 25% continued
IVI beyond
PoD 1
X X X
Avoid routine drains X (1 drain inserted) Drains removed
24–48 h postop
when used
X X (100%) X X except major
resection and this
was removed PoD
1
X X
Early removal of IDC X No IDC in procedures
<180 mins
X X (65%) X X X PoD 1 X X
Multimodal analgesic X Epidural (95%) i.v. matamizol and i.v.
paracetamol
X X (100%) X X i.v. PCA and
paracetamol,
then ibuprofen
X Epidural followed
by gabapentin,
celocoxib and
paracetamol
X Epidural
removed
PoD 3 then
NSAIDS
X
Early feeding X (within 4 h in
92%)
X X X (100%) X X (supplement
drink also)
X X X
Early mobilization X X X X (100%) X X (100%) X X X
IDC, indwelling urinary catheter; IVI, intravenous infusion; NGT, nasogastric tube; NSAIDs, non-steroidal anti-inflammatory drugs; PCA, patient-controlled analgesia; PoD, postoperative
day; VTE, venous thromboembolism.
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